(Q34620695)

English

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

stem cell transplantation

1 reference

based on heuristic

inferred from title

Sigitas Verselis

0 references

19

object named as

Joseph H Antin

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Yi-Bin Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Shuli Li

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Andrew A Lane

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Christine Connolly

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Candice Del Rio

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Betsy Valles

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Morgan Curtis

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Karen Ballen

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Corey Cutler

9

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Bimalangshu R Dey

10

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Areej El-Jawahri

11

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Amir T Fathi

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Vincent T Ho

13

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Amy Joyce

14

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Steven McAfee

15

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Michelle Rudek

16

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Trivikram Rajkhowa

17

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Thomas R Spitzer

20

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Mark Levis

21

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert Soiffer

22

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

17 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Biology of Blood and Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2042-2048

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Treatment of FLT3-ITD acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

FLT3: ITDoes matter in leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

7 July 2018

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Molecular remission of FLT3-ITD(+) positive AML relapse after allo-SCT by acute GVHD in addition to sorafenib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4253683

26 October 2018

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25239228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML

1 reference

https://pubmed.ncbi.nlm.nih.gov/25239228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25239228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD

1 reference

https://pubmed.ncbi.nlm.nih.gov/25239228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product

1 reference

https://pubmed.ncbi.nlm.nih.gov/25239228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.BBMT.2014.09.007

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

release_awaxink3t5gxvfq3xj25iy25zu

1 reference

https://api.fatcat.wiki/v0/release/awaxink3t5gxvfq3xj25iy25zu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34620695&oldid=1835973066"